237 |
Technical Aspects and an Update on the EU and US ZOMAXX Clinical Trials |
Alan C. Yeung |
May. 19. 06 |
236 |
DES in the Treatment of SVG |
J.Eduardo M.R. Sousa |
May. 19. 06 |
235 |
Bioabsorbable Stents |
Jacques J. Koolen |
May. 19. 06 |
234 |
SISR. A Prospective Randomized Comparison of the Sirolimus-Eluting Stent vs Brachytherapy in Patients with Bare Metal In-Stent Restenosis |
David R. Holmes |
May. 19. 06 |
233 |
Axxess Plus™: The First Drug-Eluting Stent for the Treatment of Bifurcation Lesions |
Jeffrey W. Moses |
May. 19. 06 |
232 |
Percutaneous Interventions for Patent Foramen Ovale |
Eric Eeckhout |
Oct. 06. 05 |
231 |
New Concept and Device for Ostial and Bifurcation Stenting |
Yaron Almagor |
Oct. 06. 05 |
230 |
The E-valve Edge-to-Edge Repair for Mitral Regurgitation: Design Concept and EVEREST Update |
Ted Feldman |
Oct. 06. 05 |
229 |
Drug-Eluting Stents, Late Loss, and Restenosis DES to Prevent MIs |
Richard E. Kuntz |
Sep. 29. 05 |
228 |
What Are the Proper End Points for DES Trials? |
Alan C. Yeung |
Sep. 29. 05 |